Alpha Tau Medical Ltd

DRTS

Healthcare|Biotechnology|IL

$13.72

+0.42 (+3.16%)

Tangible Book / Share

$0.48

Cash / Share

$1.11

Next Earnings Report

Nov 19, 2026

EPS est. -$0.14 · Revenue est. $243.3K

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Apr 28, 2026 (F-3). Possible dilution.

Upcoming Data Readouts (12)

Dec 2026

Est. completion

NAHead and Neck Squamous Cell Carcinoma

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

NCT05047094n=48

Dec 2026

Est. completion

NASkin Cancer

Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)

NCT03737734n=30

Dec 2026

Est. completion

NASquamous Cell Carcinoma

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients

NCT06615635n=28

Jan 2027

Est. completion

NAPancreatic Cancer

Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer

NCT06026943n=15

Jan 2027

Est. completion

NAPancreatic Cancer

Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer

NCT06755359n=40

Jan 2027

Est. completion

NASkin Cancer

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia

NCT04534127n=56

Jan 2027

Est. completion

NASkin Cancer

Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors

NCT04068155n=80

Feb 2027

Est. completion

NARecurrent Lung Cancer

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer

NCT05632913n=10

Feb 2027

Est. completion

NALiver Metastases

Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases

NCT05829291n=10

Apr 2027

Est. completion

NARecurrent Squamous Cell Carcinoma

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma

NCT05323253n=86

Apr 2027

Est. completion

NAMalignant Tumor

Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors

NCT05781555n=100

Jun 2027

Est. completion

NANon-metastatic Prostate Cancer

Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.

NCT06202248n=10

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026

Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

NCT06698458

Oct 2026

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer

NCT04002479

Recent Press Releases

Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange

Oct 29, 2026 · GlobeNewsWire

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

Oct 22, 2026 · GlobeNewsWire

Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting

Oct 19, 2026 · GlobeNewsWire

Alpha Tau to Participate in October Investor Conferences

Oct 5, 2026 · GlobeNewsWire

Alpha Tau to Participate in September Investor Conferences

Sep 2, 2026 · GlobeNewsWire

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

Aug 31, 2026 · GlobeNewsWire

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Aug 10, 2026 · GlobeNewsWire

SEC Filings (71)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Oct 29, 2026	6-K	Foreign issuer report	Document Index
Oct 22, 2026	6-K	Foreign issuer report	Document Index
Oct 19, 2026	6-K	Foreign issuer report	Document Index
Aug 31, 2026	6-K	Foreign issuer report	Document Index
Aug 10, 2026	6-K	Foreign issuer report	Document Index
Aug 10, 2026	6-K	Foreign issuer report	Document Index
Jul 21, 2026	6-K	Foreign issuer report	Document Index
Jul 15, 2026	6-K	Foreign issuer report	Document Index
Jun 25, 2026	6-K	Foreign issuer report	Document Index
Jun 23, 2026	6-K	Foreign issuer report	Document Index
Jun 11, 2026	6-K	Foreign issuer report	Document Index
Jun 3, 2026	6-K	Foreign issuer report	Document Index
Jun 1, 2026	6-K	Foreign issuer report	Document Index
May 18, 2026	6-K	Foreign issuer report	Document Index
May 18, 2026	6-K	Foreign issuer report	Document Index
May 11, 2026	6-K	Foreign issuer report	Document Index
May 11, 2026	6-K	Foreign issuer report	Document Index
May 8, 2026	6-K	Foreign issuer report	Document Index
May 8, 2026	6-K	Foreign issuer report	Document Index
May 7, 2026	6-K	Foreign issuer report	Document Index
May 5, 2026	6-K	Foreign issuer report	Document Index
May 4, 2026	6-K	Foreign issuer report	Document Index
May 1, 2026	EFFECT		Document Index
Apr 28, 2026	F-3	Shelf registration	Document Index
Apr 27, 2026	6-K	Foreign issuer report	Document Index
Apr 23, 2026	6-K	Foreign issuer report	Document Index
Mar 31, 2026	6-K	Foreign issuer report	Document Index
Mar 9, 2026	S-8	Employee stock plan	Document Index
Mar 9, 2026	6-K	Foreign issuer report	Document Index
Mar 9, 2026	20-F	Annual report (foreign)	Document Index
Feb 24, 2026	6-K	Foreign issuer report	Document Index
Jan 29, 2026	6-K	Foreign issuer report	Document Index
Jan 6, 2026	6-K	Foreign issuer report	Document Index
Jan 5, 2026	6-K	Foreign issuer report	Document Index
Dec 18, 2025	6-K	Foreign issuer report	Document Index
Dec 9, 2025	6-K	Foreign issuer report	Document Index
Dec 4, 2025	6-K	Foreign issuer report	Document Index
Dec 2, 2025	6-K	Foreign issuer report	Document Index
Nov 20, 2025	6-K	Foreign issuer report	Document Index
Oct 21, 2025	6-K	Foreign issuer report	Document Index